Proposal for new Banff Working Group: Transplantation HIV+ to HIV+

Serena M Bagnasco, MD Johns Hopkins School of Medicine Department of Pathology

sbagnas1@jhmi.edu

Serena M Bagnasco, MD Disclosures

Current: Shire ViroPharma, Inc.- Local pathologist in multicenter study Previous: Alexion – Local pathologist in multicenter study


No relevance to this presentation


CKD/ESRD in HIV

- 10-30% prevalence of chronic kidney disease
 - HIV-associated nephropathy, IC GN
 - Antiretroviral toxicity
 - Hypertension, diabetes, cardiovascular
- More than 10,000 HIV+ individuals on dialysis
- 14 fold increase in prevalent cases between 1999-2010
- Shorter survival of HIV+ individuals with ESRD than HIV- subjects
- Transplantation has become available for HIV+ subjects in US and in other countries, with good outcomes

Lucas G/Kalayjian R. CID 2014; SRTR data Ahuja et al. JASN 2002 Bickel et al. HIV Med 2013

Transplantation HIV- to HIV+





ORIGINAL ARTICLE

Outcomes of Kidney Transplantation in HIV-Infected Recipients

Peter G. Stock, M.D., Ph.D., Burc Barin, M.S., Barbara Murphy, M.D., Douglas Hanto, M.D., Ph.D., Jorge M. Diego, M.D., Jimmy Light, M.D., Charles Davis, M.D., Emily Blumberg, M.D., David Simon, M.D., Ph.D., Aruna Subramanian, M.D., J. Michael Millis, M.D., G. Marshall Lyon, M.D., Kenneth Brayman, M.D., Doug Slakey, M.D., Ron Shapiro, M.D., Joseph Melancon, M.D., Jeffrey M. Jacobson, M.D., Valentina Stosor, M.D., Jean L. Olson, M.D., Donald M. Stablein, Ph.D., and Michelle E. Roland, M.D. for the HIV-TR Investigators

Stock PG et al NEJM 2010;363:2004-2014.

N = 150

Patient survival 1 yr: 95%; 3 yr: 91%

Graft survival 1 yr: 90%; 3 yr: 77% <u>Kumar MS</u>¹, et al: Safety and success of kidney transplantation and concomitant immunosuppression in HIVpositive patients (n=40, US). <u>Kidney Int.</u> 2005 Apr;67(4):1622-9

Patient:1yr:85%;2yr:82%Graft:1yr:75%;2yr:71%

Qiu J¹, et al: HIV-positive renal recipients can achieve survival rates similar to those of HIV-negative patients (n=38, US) <u>Transplantation.</u> 2006 Jun 27;81(12):1658-61.

Patient: 5yr: 91% Graft: 5yr: 76%

Touzot M¹, et al: Renal transplantation in HIV-infected patients: the Paris experience (n= 27). Am J Transplant. 2010 Oct;10(10):2263-9. Patient: 1yr: 100%; 2yr: 98% Graft: 1yr: 98%; 2yr: 96%

Gathogo EN¹, et al: Kidney transplantation in HIV-positive adults: the UK experience (n=35). Int J STD AIDS. 2014 Jan;25(1):57-66. Patient: 1yr: 91%; 3yr: 91% Graft: 1yr: 91%; 3yr: 84%



South Africa Experience


The NEW ENGLAND JOURNAL of MEDICINE

Muller et al, NEJM 2015: 372:613-620 HIV+ to HIV+ kidney transplantation: Results at 3 and 5 years



Graft and patient survival among 27 HIV+ patients who received Kidney transplant from HIV+ donor

Graft survival: 1 year 93% 3 years 84% 5 years 84%



National Organ Transplant Act, 1984/88 42 CFR 121.6 Sect 372(b): *"requires the* Organ Procurement and Transplant Network (*OPTN*) to adopt and use standards for preventing the acquisition of organs from individuals known to be infected with HIV."

HOPE (HIV Organ Policy Equity HOPE ACT)

Passed by US Congress in November 2013, DHHS revoked ban on HIV+ donors in June 2015 Legalized transplant from HIV+ donor to HIV+ recipients Only in the setting of an approved research protocol

- Directs the Secretary to revise current regulations (specifically, 42 CFR 121.6)
- Directs Secretary to publish research criteria relating to HIV+ to HIV+ transplant
- Requires the OPTN to revise standards for the acquisition and transportation of donated HIV+ organs
- The HOPE Act states that "not later than 4 years after the date of enactment and annually thereafter, the Secretary shall review the results of scientific research in conjunction with the OPTN to determine whether the results warrant revision of the standards of quality."


Estimating the Potential Pool of HIV-Infected Deceased Organ Donors in The United States

• 500-600 donors per year

B.J. Boyarsky et al American Journal of Transplantation 2011, 11: 1209-1217

Increased incidence of rejection in HIV+ recipients


Variable incidence of rejection in different studies in cohorts from different nations



Key differences: US and S Africa

	South Africa	US
Population	53 million	316 million
Persons living with HIV	5.6 million	1.1 million
HIV+ prevalence	17.8%	0.6%
Predominant subtype	С	В
Annual HIV+ deaths	310,000	17,000
Transmitted drug resistance	< 5%	10-18%
Transplant wait list	4300	123,992
Transplant per year	229	16,896

Durand/Segev, AJT 2015; 15:2023-30



Emory University Hospital Georgetown University Medical Center Hahnemann University Hospital Hospital of the University of Pennsylvania The Johns Hopkins Hospital Massachusetts General Hospital

Nount Sinai Medical Center Northwestern Memorial Hospital Rush University Medical Center University of Alabama at Birmingham University of California, San Francisco University of Maryland Medical System Weill Cornell Medical Center Yale New Haven Hospital Non inferiority of kidney transplants from HIV+ deceased donors compared to kidney transplants from an HIV-negative donors

Primary Endpoints

Composite event HIV related complications

- HIV breakthrough or virologic failure
- AIDS defining illness
- Allograft rejection


Secondary outcomes

- Patient survival
- Graft survival
- Graft function
- Donor specific antibodies at 1 year
- HIV viral load
- CD4 count
- ART resistance
- X4 virus

- Non AIDS infections
- Surgical complications
- HIV-associated renal disease
- Viral malignancies

Pathology

- Allograft rejection
- Drug toxicity and interstitial nephritis (anti-retroviral, anti rejection, others)
- HIV associated Nephropathy (HIVAN)
- Immune Complex mediated glomerulopathies
- FSGS without HIVAN features
- Superinfection
- Infection involving the graft
- Diabetes
- Thrombotic microangiopathy
- Paraprotein-related disease




	LIGHT MICROSCOPY			ELECTRON MICROSCOPY	
	(not Banff)				
	Glomeruli total N			Glomeruli (n examined)	
	Glom Global sclerosis N	Pathologi	c Features	GBM folded/wrinkled	
Banff score summary	Glom Segm sclerosis N			GBM thickness: normal, increased, lov	Adequacy (Y/N)
-	Glom Ischemic changes			(nm)	No rejection/Unremarkable
Banff scores (0,1,2,3)	Glom fibrin thrombi			GBM widened subendothelial space	Borderline for rejection
g	Glom fragmented RBC			GBM cytoplasmic interposition /	Rejection
i	Glom hypercellularity	IF	IMMUNOSTAINS	double contours	Cell mediated IA
t	Glom necrotizing lesion	IF		Endothelial cells enlarged	Cell mediated IB
v	Glom crescents	lgG (0,1+,2+,3+,4+)	SV40	Endothelial loss of fenestration	Cell mediated IIA
ah	Glom collapsing	lgA	EB in situ (EBER)	Intracapillary inflammatory cells	Cell mediated IIB
cg	changes	lgM	CMV	Podocyte enlargement	Antibody mediated active
ci (% cortex)	Glom mesangiolysis	C3	Adenovirus	Podocyte microvillous transformation	Antibody mediated active
	Tubules	C1q	Herpes V	Podocyte foot process effacement	Concerning for AMR check DSA
cv	Tubular injury	-	Kappa V	present: %	Mixed rejection
mm	Isometric vacuolization	Kappa Lambda	Lambda	Mesangial expansion	Isolated V lesion
CV	Microcystic changes	Albumin	lgG4	Deposits (present/absent)	Thrombotic microangiopathy
ti	Viral Cytopatic changes	Fibrinogen	C4d	Deposits Localization: subepithelial	Tubular injury
	BK, CMV, Adeno	PLA2R	(CD3, CD20, CD68,	intramembranou	BK nephropathy
C4d (0,1,2,3)	(specify)	lgG 1	(CD3, CD20, CD08, CD34)	subendothelial	Pyelonephritis/Infection
(-, , , -,	Interstitium	lgG 2	CD34)	mesangial	HIVAN
	Edema	lgG 3		Deposit substructure	FSGS
	Inflammation cell type	lgG 4		Tubuloreticular inclusions in endothel	HIVICK
	Lymphocytes	igu 4		cells	Glomerulopathies (other)
	Plasmacells	C4d		Peritubular capillaries basal lamina N	Giomerulopatilles (other)
	Neutrophils	C4d C3d		layers	
	Eosinophils (> 5/20X			Deposits in tubular basement	
	HPF)			membrane	
	Histiocytes			Tubular cell crystalline inclusions	
		-		Tubular mitochondrial abnormalities	

	LIGHT MICROSCOPY			ELECTRON MICROSCOPY					
	(not Banff)	Pathologic Features							
	Glomeruli total N			Glomeruli (n examined)					
	Glom Global sclerosis N					FINAL DIAGNOSIS:			
Banff score summary	Glom Segm sclerosis N	0		GBM thickness: normal, increased, lo		equacy (Y/N)			
	Glom Ischemic changes			(nm)		rejection/Unremarkable			
Banff scores (0,1,2,3)	Glom fibrin thrombi			GBM widened subendothelial space		derline for rejection			
g	Glom fragmented RBC			GBM cytoplasmic interposition /		ection			
i	Glom hypercellularity	IF	IMMUNOSTAINS	double contours		mediated IA			
t	1_1					mediated IB			
v						mediated IIA			
ah	Uniform and detailed histological analysis of biopsy tissue mediated IIB								
cg		lu uetalleu i	listological	allalysis of blopsy tissu	e	oody mediated active			
ci (% cortex)						oody mediated chronic			
ct (% cortex)		. .				erning for AMR check DSA			
cv	Correlation of morphological tissue interrogation with								
mm		-	-	•		ted V lesion			
CV	cinical, mo	lecular and	experiment	al data collected on		mbotic microangiopathy			
ti	transplant	donors and	recipients.			lar injury			
ptc (0,1,2,3), focal/diffuse						ephropathy			
C4d (0,1,2,3)						onephritis/Infection			
		llgG 2		ากตรงสาเหล่า	HIV				
	Edema	lgG 3		Deposit substructure	FSG	S			
	Inflammation cell type	lgG 4		Tubuloreticular inclusions in endothel	HIVI	ІСК			
	Lymphocytes			cells	Glor	merulopathies (other)			
	Plasmacells	C4d		Peritubular capillaries basal lamina N					
	Neutrophils	C3d		layers					
	Eosinophils (> 5/20X		ı	Deposits in tubular basement					
	HPF)			membrane					
	Histiocytes			Tubular cell crystalline inclusions					
				Tubular mitochondrial abnormalities					

Digital Pathology

- Remote access by multiple users
- Ideal for multicenter studies

- Application of multiple scoring systems to same material in different studies
- Permanent library of data/images
- Platform for digital repositories




Digital Pathology

- Remote access by multiple users
- Ideal for multicenter studies

- Application of multiple scoring systems to same material in different studies
- Permanent library of data/images
- Platform for digital repositories

First: are we all on the same page?



Digital Pathology

- Remote access by multiple users
- Ideal for multicenter studies

- Application of multiple scoring systems to same material in different studies
- Permanent library of data/images
- Platform for digital repositories
- Test concordance on features and diagnoses on allograft biopsies:

 Whole slide imaging (WSI) of slides, digital images IF and EM accessible through a website
 Scoring sheet for LM, IF and EM features and diagnoses of each case
 Webinars
- Test reproducibility: Apply agreed scoring method to a sufficiently large number of available WSI of HIV allograft biopsies to examine the reproducibility of scoring among participating pathologists
- Examine relation / predictive value of specific features and diagnoses to rates of deterioration of graft function, selected outcomes, selected clinical/research parameters.
- Facilitate comparisons of results from different clinical trial

SUMMARY

- HIV+ to HIV+ transplantation offers additional options for HIV+ patients with ESRD and liver failure. A number of national and international centers are embarking in HIV+ to HIV+ transplantation.
- HIV+ transplant recipients pose specific challenges
- Consensus on standardized histology diagnostic criteria for graft rejection as well as uniform criteria for evaluation of HIV-related allograft lesions is needed. Adherence to uniform histologic criteria are important in multicenter clinical trials.
- The main goal of this new Banff working group is to gather US and international pathologists and specialists from different medical fields to share their experience, and to develop consensus and evidencebased guidelines for these types of transplants.

THANK YOU